Boehringer Ingelheim is selling its Roxane business, which combines the operations of Roxane Laboratories Inc. and Boehringer Ingelheim Roxane Inc., to Hikma Pharmaceuticals PLC for approximately $2.65 billion. Roxane is a well-established U.S. specialty generics company with a highly differentiated product portfolio and best-in-class R&D capabilities. The deal transforms Hikma’s position in the U.S. generics market, establishing it as the sixth largest company by revenue. At the same ...